Author

J. Saarela

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Assay:bulk RNA-seq· 2 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Assay:clinical cohort / trial· 1 Approach:deep learning· 1

Frequent Co-Authors

A. Jackson· 1 shared A. Ranki· 1 shared A. T. Dinkova-Kostova· 1 shared C. A. Heckman· 1 shared E. Einarsdottir· 1 shared E. Gholizadeh· 1 shared E. Haapaniemi· 1 shared E. Kulesskiy· 1 shared

Activity by Year

2018-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 12 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Jackson

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Designing patient-oriented combination therapies for acute myeloid leukemia based on efficacy/toxicity integration and bipartite network modeling

M. Mirzaie, E. Gholizadeh, J. J. Miettinen, T. Ruokoranta, F. Ianevski, J. Saarela, M. Manninen, S. Miettinen, C. A. Heckman, M. Jafari

This paper identifies effective and low-toxicity drug combinations for AML using a bipartite network model and patient-derived data, finding ruxolitinib-ulixertinib and sapanisertib-LY3009120 as the most synergistic.

bioRxiv · May 25, 2023Cancer Biology

The kinase inhibitor AT9283 selectively kills colorectal cancer cells with hyperactive NRF2

L. Torrente, G. Maan, L. Casares, A. Jackson, T. Honda, G. Wells, E. Kulesskiy, J. Saarela, A. T. Dinkova-Kostova, L. de la Vega

The paper identifies AT9283 as a drug that selectively kills colorectal cancer cells with hyperactive NRF2, showing its potential as a therapeutic target.

bioRxiv · Oct 21, 2019 · PreprintCancer Biology

Characterization of novel TMEM173 mutation with additive IFIH1 risk allele

S. Keskitalo, E. Haapaniemi, E. Einarsdottir, K. Rajamaki, H. Heikkila, M. Ilander, M. Poyhonen, E. Morgunova, K. Hokynar, S. Lagstrom, S. Kivirikko, S. Mustjoki, K. Eklund, J. Saarela, J. Kere, , M. Varjosalo

The paper reports a novel gain-of-function TMEM173 mutation and its additive effects with IFIH1 risk allele on clinical phenotype in a multigeneration family.

bioRxiv · Aug 17, 2018Immunology